These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28622326)

  • 1. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
    Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
    Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept versus ranibizumab for treating persistent diabetic macular oedema.
    Vandekerckhove KR
    Int Ophthalmol; 2015 Aug; 35(4):603-9. PubMed ID: 25989873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.
    Plaza-Ramos P; Borque E; García-Layana A
    PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
    Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
    Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.
    Lindboe JB; Brynskov T; Sørensen TL; Schmidt Laugesen C
    Acta Ophthalmol; 2024 Jun; 102(4):e661-e662. PubMed ID: 38525896
    [No Abstract]   [Full Text] [Related]  

  • 12. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
    Hogg HJ; Di Simplicio S; Pearce MS
    Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
    Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
    Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
    [No Abstract]   [Full Text] [Related]  

  • 14. Are the real-life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?
    Higham AK; Tahir MI; Gala K; Verroiopoulos G
    Acta Ophthalmol; 2019 Mar; 97(2):e322-e323. PubMed ID: 30369094
    [No Abstract]   [Full Text] [Related]  

  • 15. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
    Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
    Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept: A Review of Its Use in Diabetic Macular Oedema.
    Keating GM
    Drugs; 2015 Jul; 75(10):1153-60. PubMed ID: 26056030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.